Matthew Ruth Biography and Net Worth

Matthew Ruth brings significant commercial experience to Opiant. Matt served as SVP and Chief Commercial Officer at Adapt Pharma Ltd, where he led the launch and commercialization of the first nasal naloxone spray approved by the U.S. Food and Drug Administration to treat opioid overdose. Prior to his work in the opioid overdose space, Matt was Chief Operating Officer for RightCare Solutions, a medical technology company, where he built their commercial infrastructure and was instrumental in building a revenue stream that enabled their acquisition by NaviHealth in 2015. Before that, Matt was Vice President of Azur Pharma, responsible for the CNS franchise which was acquired by Jazz Pharmaceuticals. Earlier in his career, Matt worked at Avanir Pharmaceuticals and Allergan.

What is Matthew R. Ruth's net worth?: The estimated net worth of Matthew R. Ruth is at least $0.00 as of July 20th, 2022. Mr. Ruth owns 29,916 shares of Opiant Pharmaceuticals stock worth more than $0 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Ruth may own. Learn More about Matthew R. Ruth's net worth.
How do I contact Matthew R. Ruth?: The corporate mailing address for Mr. Ruth and other Opiant Pharmaceuticals executives is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. Opiant Pharmaceuticals can also be reached via phone at (310) 598-5410 and via email at [email protected]. Learn More on Matthew R. Ruth's contact information.
Has Matthew R. Ruth been buying or selling shares of Opiant Pharmaceuticals?: Matthew R. Ruth has not been actively trading shares of Opiant Pharmaceuticals in the last ninety days. Most recently, Matthew R. Ruth sold 1,084 shares of the business's stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $10.62, for a transaction totalling $11,512.08. Following the completion of the sale, the insider now directly owns 29,916 shares of the company's stock, valued at $317,707.92. Learn More on Matthew R. Ruth's trading history.
Who are Opiant Pharmaceuticals' active insiders?: Opiant Pharmaceuticals' insider roster includes Craig Collard (Director), Roger Crystal (CEO), David O'Toole (CFO), Matthew Ruth (Insider), Michael Sinclair (Director), Phil Skolnick (Insider), and Thomas Thomas (Director). Learn More on Opiant Pharmaceuticals' active insiders.

Matthew R. Ruth Insider Trading History at Opiant Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/20/2022	Sell	1,084	$10.62	$11,512.08	29,916
8/31/2021	Buy	2,000	$17.34	$34,680.00	17,000

Matthew R. Ruth Buying and Selling Activity at Opiant Pharmaceuticals

Opiant Pharmaceuticals Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Today's Range

Now: N/A

50 Day Range

MA: $20.58

$20.03

$21.10

2 Week Range

Now: N/A

Volume

562,700 shs

Average Volume

77,920 shs

Market Capitalization

$108.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.